Compare AU

Compare CURE vs. GLOB

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Barrow Hanley Global Share Fund (Managed Fund) (GLOB). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

GLOB

Popularity

Low

Low

Pearlers invested

82

5

Median incremental investment

$619.50

$992.24

Median investment frequency

Monthly

Monthly

Median total investment

$1,323.41

$4,422.04

Average age group

> 35

26 - 35


Key Summary

CURE

GLOB

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

GLOB.AX was created on 2022-06-06 by Barrow Hanley. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to provide investors with long-term capital growth through investment in quality global shares and to outperform the MSCI World Net Total Return Index (AUD) (before fees and taxes) over rolling three-year periods.

Top 3 holdings

Natera Inc (3.41 %)

Incyte Corp (2.94 %)

Gilead Sciences Inc (2.88 %)

Bank of Nova Scotia (3.31 %)

Comcast Corp Class A (2.93 %)

Merck & Co Inc (2.90 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Health Care (20.87 %)

Utilities (18.30 %)

Financials (12.59 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

United States (51.22 %)

France (7.50 %)

Canada (7.35 %)

Management fee

0.45 %

0.99 %


Key Summary

CURE

GLOB

Issuer

Global X

Barrow Hanley

Tracking index

S&P Biotechnology Select Industry

MSCI World Index

Asset class

ETF

ETF

Management fee

0.45 %

0.99 %

Price

$49.94

$4.76

Size

$38.065 million

N/A

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

3.54 %

Market

ASX

ASX

First listed date

12/11/2018

05/06/2022

Purchase fee

$6.50

$6.50


Community Stats

CURE

GLOB

Popularity

Low

Low

Pearlers invested

82

5

Median incremental investment

$619.50

$992.24

Median investment frequency

Monthly

Monthly

Median total investment

$1,323.41

$4,422.04

Average age group

> 35

26 - 35


Pros and Cons

CURE

GLOB

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher price growth

Cons

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

GLOB

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home